- idUS
- Listar por autor
Listar por autor "Fasching, P. A."
Mostrando ítems 1-2 de 2
-
Artículo
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Slamon, D. J.; Neven, P.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S.; Cruz Merino, Luis de la; Fasching, P. A. (Elsevier, 2021)Background: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) ...
-
Artículo
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving frst-line ribociclib plus fulvestrant
Neven, P.; Fasching, P. A.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S. A.; Cruz Merino, Luis de la; Slamon, D. J. (Biomed Central LTD, 2023)Background The phase III MONALEESA-3 trial included frst- (1L) and second-line (2L) patients and demonstrated a signifcant ...